Reports

As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

Global Exocrine Pancreatic Insufficiency Treatment Market: By Disease Management: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Others; By Diagnosis; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics: SWOT Analysis; Competitive Landscape; Industry Events and Developments

Global Exocrine Pancreatic Insufficiency Treatment Market Outlook

The global exocrine pancreatic insufficiency treatment market attained a value of more than USD 3.6 billion in 2021. The market is further expected to grow at a CAGR of 8.27% during the forecast period of 2022-2027 to reach above USD 5.8 billion by 2027.

 

Increasing Prevalence of EPI Causing Disorders is Aiding the Market Growth of Exocrine Pancreatic Insufficiency Treatment

The global market for exocrine pancreatic insufficiency treatment is being driven by the increasing prevalence of chronic pancreatic and cystic fibrosis amongst the geriatric populations. In addition, cystic fibrosis has been increasingly found in young children and people in early adulthood, leading to a rise in the number of people suffering from exocrine pancreatic insufficiency, and hence augmenting the demand for an effective treatment, thereby contributing to the market growth.

 

Global Exocrine Pancreatic Insufficiency Treatment Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Furthermore, owing to sedentary lifestyles and unhealthy eating habits, the spur in the global cases of diabetes is a leading cause of exocrine pancreatic insufficiency. However, increasing awareness regarding the impact of exocrine pancreatic insufficiency on human health resulting in disturbances in normal growth, reduced life expectancy, and lowered immunity levels have stimulated the growth of the market.

 

Exocrine Pancreatic Insufficiency Treatment: Industry Definition and Segmentation

Exocrine pancreatic insufficiency (EPI) refers to a medical condition characterised by the inability to properly digest food due to insufficient levels of digestive enzymes produced by pancreas. The disease is most commonly detected by clinical tests such as blood, stool, malabsorption, and pancreatic function tests. Exocrine pancreatic insufficiency treatment includes all types of disease management to help the patient recover from exocrine pancreatic insufficiency.

On the basis of disease management, the market can be divided into:

  • Nutritional Management
  • Pancreatic Enzyme Replacement Therapy (PERT)
  • Lifestyle Modifications approach

Based on diagnosis, the market can be segmented into:

  • Magnetic Resonance Imaging (MRI)
  • CT Scanning
  • Endoscopic ultra-sonography (EUS)
  • Blood Tests
  • Others

The EMR report looks into the regional markets of exocrine pancreatic insufficiency treatment like North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.

 

Increasing Pharmaceutical Investments in R&D Activities to Augment the Market Growth of Exocrine Pancreatic Insufficiency Treatment

The rising focus on pharmaceutical research and development (R&D) for an effective treatment method is significantly contributing to the overall growth of the market. In order to address the increasing demand for the treatment of exocrine pancreatic insufficiency, key industry players, in conjunction with governing agencies, are significantly contributing towards the development of a cure, hence pushing the growth of the market. In addition to this, the strong market penetration of significant pipeline drugs is further substantially contributing to the overall market growth of exocrine pancreatic insufficiency treatment. Moreover, the emergence of new chemical entities (NCEs) in different parts of the world and rising focus on nutritional diet are expected to have a positive influence on the market growth in the coming years.

 

Key Industry Players in the Global Exocrine Pancreatic Insufficiency Treatment Market

The report presents a detailed analysis of the following key players in the global exocrine pancreatic insufficiency treatment market, looking into their capacity, market share, and latest developments like capacity expansions, plant turnabouts and mergers and acquisitions:

  • AbbVie Inc.
  • Janssen Global Services, LLC
  • Chiesi Farmaceutici S.p.A.
  • Nordmark Arzneimittel GmbH and Co. KG
  • Digestive Care, Inc
  • Cilian AG
  • Anthera Pharmaceuticals, Inc.
  • Allergan plc.
  • First Wave BioPharma, Inc. (AzurRx)
  • Aptalis Pharma Inc.
  • Others

The comprehensive report looks at the micro and macro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of the Porter’s Five Forces Model.

 

REPORT FEATURES DETAILS
Base Year 2021
Historical Period 2017-2021
Forecast Period 2022-2027
Scope of the Report Historical and Forecast Trends, Industry Drivers and Constraints, Historical and
Forecast Market Analysis by Segment- Disease Management, Diagnosis, Region
Breakup by Disease Management Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications approach
Breakup by Diagnosis Magnetic Resonance Imaging (MRI), CT Scanning, CT Scanning, Blood Tests, Others
Breakup by Region North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Market Dynamics SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand
Competitive Landscape Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications
Companies Covered AbbVie Inc., Janssen Global Services, LLC, Chiesi Farmaceutici S.p.A.,
Nordmark Arzneimittel GmbH and Co. KG, Digestive Care, Inc, Cilian AG,
Anthera Pharmaceuticals, Inc., Allergan plc., First Wave BioPharma, Inc. (AzurRx), Aptalis Pharma Inc., Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Exocrine Pancreatic Insufficiency Treatment Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Exocrine Pancreatic Insufficiency Treatment Historical Market (2017-2021) 
    8.3    Global Exocrine Pancreatic Insufficiency Treatment Market Forecast (2022-2027)
    8.4    Global Exocrine Pancreatic Insufficiency Treatment Market by Disease Management
        8.4.1    Nutritional Management
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2017-2021)
            8.4.1.3    Forecast Trend (2022-2027)
        8.4.2    Pancreatic Enzyme Replacement Therapy (PERT)
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2017-2021)
            8.4.2.3    Forecast Trend (2022-2027)
        8.4.3    Lifestyle Modifications approach
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2017-2021)
            8.4.3.3    Forecast Trend (2022-2027)
    8.5    Global Exocrine Pancreatic Insufficiency Treatment Market by Diagnosis
        8.5.1    Magnetic Resonance Imaging (MRI)
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2017-2021)
            8.5.1.3    Forecast Trend (2022-2027)
        8.5.2    CT Scanning
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2017-2021)
            8.5.2.3    Forecast Trend (2022-2027)
        8.5.3    Endoscopic ultra-sonography (EUS)
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2017-2021)
            8.5.3.3    Forecast Trend (2022-2027)
        8.5.4    Blood Tests
            8.5.4.1    Market Share
            8.5.4.2    Historical Trend (2017-2021)
            8.5.4.3    Forecast Trend (2022-2027)
        8.5.5    Others
    8.6    Global Exocrine Pancreatic Insufficiency Treatment Market by Region
        8.6.1    Market Share
            8.6.1.1    North America
            8.6.1.2    Europe
            8.6.1.3    Asia Pacific
            8.6.1.4    Latin America
            8.6.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2017-2021)
        9.1.2    Forecast Trend (2022-2027)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2017-2021)
        9.2.2    Forecast Trend (2022-2027)
        9.2.3    Breakup by Country
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2017-2021)
        9.3.2    Forecast Trend (2022-2027)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2017-2021)
        9.4.2    Forecast Trend (2022-2027)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2017-2021)
        9.5.2    Forecast Trend (2022-2027)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    EMR’s Key Indicators for Demand
    10.4    EMR’s Key Indicators for Price
11    Competitive Landscape
    11.1    Market Structure
    11.2    Company Profiles
        11.2.1    AbbVie Inc.
            11.2.1.1    Company Overview
            11.2.1.2    Product Portfolio
            11.2.1.3    Demographic Reach and Achievements
            11.2.1.4    Certifications
        11.2.2    Janssen Global Services, LLC
            11.2.2.1    Company Overview
            11.2.2.2    Product Portfolio
            11.2.2.3    Demographic Reach and Achievements
            11.2.2.4    Certifications
        11.2.3    Chiesi Farmaceutici S.p.A.
            11.2.3.1    Company Overview
            11.2.3.2    Product Portfolio
            11.2.3.3    Demographic Reach and Achievements
            11.2.3.4    Certifications
        11.2.4    Nordmark Arzneimittel GmbH and Co. KG
            11.2.4.1    Company Overview
            11.2.4.2    Product Portfolio
            11.2.4.3    Demographic Reach and Achievements
            11.2.4.4    Certifications
        11.2.5    Digestive Care, Inc
            11.2.5.1    Company Overview
            11.2.5.2    Product Portfolio
            11.2.5.3    Demographic Reach and Achievements
            11.2.5.4    Certifications
        11.2.6    Cilian AG
            11.2.6.1    Company Overview
            11.2.6.2    Product Portfolio
            11.2.6.3    Demographic Reach and Achievements
            11.2.6.4    Certifications
        11.2.7    Anthera Pharmaceuticals, Inc.
            11.2.7.1    Company Overview
            11.2.7.2    Product Portfolio
            11.2.7.3    Demographic Reach and Achievements
            11.2.7.4    Certifications
        11.2.8    Allergan plc.
            11.2.8.1    Company Overview
            11.2.8.2    Product Portfolio
            11.2.8.3    Demographic Reach and Achievements
            11.2.8.4    Certifications
        11.2.9    First Wave BioPharma, Inc. (AzurRx)
            11.2.9.1    Company Overview
            11.2.9.2    Product Portfolio
            11.2.9.3    Demographic Reach and Achievements
            11.2.9.4    Certifications
        11.2.10    Aptalis Pharma Inc.
            11.2.10.1    Company Overview
            11.2.10.2    Product Portfolio
            11.2.10.3    Demographic Reach and Achievements
            11.2.10.4    Certifications
        11.2.11    Others
12    Industry Events and Developments

 

List of Figures and Tables

1.    Global Exocrine Pancreatic Insufficiency Treatment Market: Key Industry Highlights, 2017 and 2027
2.    Global Exocrine Pancreatic Insufficiency Treatment Historical Market: Breakup by Disease Management (USD Billion), 2017-2021
3.    Global Exocrine Pancreatic Insufficiency Treatment Market Forecast: Breakup by Disease Management (USD Billion), 2022-2027
4.    Global Exocrine Pancreatic Insufficiency Treatment Historical Market: Breakup by Diagnosis (USD Billion), 2017-2021
5.    Global Exocrine Pancreatic Insufficiency Treatment Market Forecast: Breakup by Diagnosis (USD Billion), 2022-2027
6.    Global Exocrine Pancreatic Insufficiency Treatment Historical Market: Breakup by Region (USD Billion), 2017-2021
7.    Global Exocrine Pancreatic Insufficiency Treatment Market Forecast: Breakup by Region (USD Billion), 2022-2027
8.    North America Exocrine Pancreatic Insufficiency Treatment Historical Market: Breakup by Country (USD Billion), 2017-2021
9.    North America Exocrine Pancreatic Insufficiency Treatment Market Forecast: Breakup by Country (USD Billion), 2022-2027
10.    Europe Exocrine Pancreatic Insufficiency Treatment Historical Market: Breakup by Country (USD Billion), 2017-2021
11.    Europe Exocrine Pancreatic Insufficiency Treatment Market Forecast: Breakup by Country (USD Billion), 2022-2027
12.    Asia Pacific Exocrine Pancreatic Insufficiency Treatment Historical Market: Breakup by Country (USD Billion), 2017-2021
13.    Asia Pacific Exocrine Pancreatic Insufficiency Treatment Market Forecast: Breakup by Country (USD Billion), 2022-2027
14.    Latin America Exocrine Pancreatic Insufficiency Treatment Historical Market: Breakup by Country (USD Billion), 2017-2021
15.    Latin America Exocrine Pancreatic Insufficiency Treatment Market Forecast: Breakup by Country (USD Billion), 2022-2027
16.    Middle East and Africa Exocrine Pancreatic Insufficiency Treatment Historical Market: Breakup by Country (USD Billion), 2017-2021
17.    Middle East and Africa Exocrine Pancreatic Insufficiency Treatment Market Forecast: Breakup by Country (USD Billion), 2022-2027
18.    Global Exocrine Pancreatic Insufficiency Treatment Market Structure

Key Questions Answered in the Report

The global exocrine pancreatic insufficiency treatment market attained a value of more than USD 3.6 billion in 2021.

The market is projected to grow at a CAGR of 8.27% in the forecast period of 2022-2027.

The market is estimated to witness a healthy growth in the forecast period of 2022-2027 to reach above USD 5.8 billion by 2027.

The market is being driven by the increasing prevalence of exocrine pancreatic insufficiency causing disorders including cystic fibrosis and diabetes, owing to sedentary lifestyles and unhealthy diets.

The market is expected to be determined by the development of effective treatments as a result of robust expenditure on pharmaceutical research and development.

The major regional markets for exocrine pancreatic insufficiency treatment are North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.

The significant types of disease management of exocrine pancreatic insufficiency treatment are nutritional management, pancreatic enzyme replacement therapy (PERT), and lifestyle modifications approach.

The major diagnostics of exocrine pancreatic insufficiency treatment are magnetic resonance imaging (MRI), CT scanning, endoscopic ultra-sonography (EUS), and blood tests, among others.

The major players in the industry are AbbVie Inc., Janssen Global Services, LLC, Chiesi Farmaceutici S.p.A., Nordmark Arzneimittel GmbH and Co. KG, Digestive Care, Inc, Cilian AG, Anthera Pharmaceuticals, Inc., Allergan plc., First Wave BioPharma, Inc. (AzurRx), and Aptalis Pharma Inc., among others.

Analyst Review

The global exocrine pancreatic insufficiency treatment market attained a value of more than USD 3.6 billion in 2021, driven by rising prevalence of EPI causing disorders. Aided by robust investments in pharmaceutical R&D, the market is expected to grow at a CAGR of 8.27% in the forecast period of 2022-2027 to reach above USD 5.8 billion by 2027.

EMR’s meticulous research methodology delves deep into the market covering the macro and micro aspects of the industry. On the basis of disease management, the market can be divided into nutritional management, pancreatic enzyme replacement therapy (PERT), and lifestyle modifications approach. On the basis of diagnosis, the market can be categorised into magnetic resonance imaging (MRI), CT scanning, endoscopic ultra-sonography (EUS), and blood tests, among others. The major regional markets for exocrine pancreatic insufficiency treatment are North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa. The key players in the industry are AbbVie Inc., Janssen Global Services, LLC, Chiesi Farmaceutici S.p.A., Nordmark Arzneimittel GmbH and Co. KG, Digestive Care, Inc, Cilian AG, Anthera Pharmaceuticals, Inc., Allergan plc., First Wave BioPharma, Inc. (AzurRx), and Aptalis Pharma Inc., among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus providing their customers with market insights that are accurate, actionable and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

RIGHT PEOPLE

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

RIGHT METHODOLOGY

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

RIGHT PRICE

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

RIGHT SUPPORT

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports





NEWSLETTER